DCTH Stock Risk & Deep Value Analysis
Delcath Systems Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About DCTH Stock
We analyzed Delcath Systems Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran DCTH through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is DCTH Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for DCTH?
- ⚠
Slower-than-expected commercial adoption or reimbursement delays
- ⚠
Need for additional equity financing leading to significant dilution
- ⚠
Negative clinical trial results for label expansion indications
- ⚠
Competitive product development targeting similar indications
Unlock DCTH Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Delcath Systems Inc (DCTH) Do?
Market Cap
$378.15M
Sector
Healthcare
Industry
Medical Devices
Employees
96
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
Visit Delcath Systems Inc WebsiteIs DCTH Stock Undervalued?
Unlock the full AI analysis for DCTH
Get the complete DVR score, risk analysis, and more
Is DCTH Financially Healthy?
P/E Ratio
120.11
Does DCTH Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily derived from the FDA approval for Hepzato Kit in a specific indication, granting a period of exclusivity and first-mover advantage. Durability depends on successful commercialization, further label expansions, and extending patent life. The specialized nature of the treatment also creates a high barrier to entry.
Moat Erosion Risks
- •Patent expiry or challenge allowing generic competition
- •Emergence of superior or less invasive treatment options
- •Limited market size impacting long-term revenue potential without label expansion
DCTH Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive DCTH Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated late April/early May 2026)
- •Updates on Hepzato Kit commercial launch and patient uptake rates
- •Progress on securing broader reimbursement coverage
Medium-Term (6-18 months)
- •Initiation or progress of clinical trials for label expansion (e.g., intrahepatic cholangiocarcinoma, other liver cancers)
- •Potential strategic partnerships for ex-US market expansion or distribution
- •Significant milestones in physician adoption and revenue ramp-up
Long-Term (18+ months)
- •Achieving market leadership in hepatic metastatic ocular melanoma treatment
- •Successful label expansion into multiple liver-directed oncology indications
- •Sustained profitability driven by product sales
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for DCTH?
- ✓
Acceleration in Hepzato Kit sales and revenue growth quarter-over-quarter
- ✓
Improvement in cash burn rate and extension of cash runway
- ✓
Positive clinical trial data and regulatory updates for label expansion
- ✓
Securing major insurance reimbursements
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for DCTH (Delcath Systems Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
